The challenge of antimicrobial resistance in managing intra-abdominal infections

Surgical Infections

Volumn 16, Issue 3, 2015, Pages 213-220

  Sartelli, Massimo ^a   Catena, Fausto ^b   Di Saverio, Salomone ^c   Ansaloni, Luca ^d   Coccolini, Federico ^d   Tranà, Cristian ^a   Kirkby Bott, James ^e  

^a Macerata's Hospital   (Italy)

^b Maggiore Hospital   (Italy)

^c MAGGIORE HOSPITAL   (Italy)

^d PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ABDOMINAL INFECTION; ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL STRAIN; BACTEROIDES FRAGILIS; CANDIDA; ENTEROCOCCUS; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; HEALTHCARE ASSOCIATED INFECTION; HUMAN; KLEBSIELLA; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PREVALENCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; SURGICAL INFECTION; BACTERIAL INFECTIONS; CANDIDIASIS; INTRAABDOMINAL INFECTIONS; MICROBIOLOGY; MORTALITY; MULTIDRUG RESISTANCE;

BACTERIAL INFECTIONS; CANDIDIASIS; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; INTRAABDOMINAL INFECTIONS; PREVALENCE;

EID: 84930788363     PISSN: 10962964     EISSN: 15578674     Source Type: Journal    
DOI: 10.1089/sur.2013.262     Document Type: Review

References (73)

1. Menichetti F, Sganga G. Definition and classification of intra-abdominal infections. J Chemother 2009;21(Suppl 1):3-4.
2. Sartelli M. A focus on intra-abdominal infections. World J Emerg Surg 2010;19(5):9.
3. Herzog T, Chromik AM, Uhl W. Treatment of complicated intra-abdominal infections in the era of multi-drug resistant bacteria. Eur J Med Res 2010;30:525-532.
4. Barie PS, Hydo LJ, Eachempati SR. Longitudinal outcomes of intra-abdominal infection complicated by critical illness. Surg Infect 2004;5:365-373.
5. Marshall JC. Principles of source control in the early management of sepsis. Curr Infect Dis Rep 2010;12:345-353.
6. Wacha H, Hau T, Dittmer R, Ohmann C. Risk factors associated with intraabdominal infections: A prospective multicenter study. Peritonitis Study Group. Langenbecks Arch Surg 1999;384:24-32.
7. Waibel BH, Rotondo MF. Damage control for intra-abdominal sepsis. Surg Clin North Am 2012;92:243-257.
8. Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013;39:165-228.
9. Johnson AP. Improving antimicrobial stewardship: AmWeb, a tool for helping microbiologists in England to "Start Smart" when advising on antibiotic treatment. J Antimicrob Chemother 2013;68:2181-2182.
10. Shani V, Muchtar E, Kariv G, et al. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother 2010;54:4851-4863.
11. Rao GG. Risk factors for the spread of antibiotic-resistant bacteria. Drugs 1998;55:323-330.
12. Kollef MH. Optimizing antibiotic therapy in the intensive care unit setting. Crit Care 2001;5:189-195.
13. Deege MP, Paterson DL. Reducing the development of antibiotic resistance in critical care units. Curr Pharm Biotechnol 2011;12:2062-2069.
14. Paphitou NI. Antimicrobial resistance: Action to combat the rising microbial challenges. Int J Antimicrob Agents 2013;42(Suppl):S25-S28.
15. Coque TM, Baquero F, Canton R. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Eur Surveill 2008;13.
16. Michalopoulos AS, Karatza DC. Multidrug-resistant gramnegative infections: The use of colistin. Expert Rev Anti-Infect Ther 2010;8:1009-1117.
17. Friedman ND, Kaye KS, Stout JE, et al. Health careassociated bloodstream infections in adults: A reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002;137:791-797.
18. Sartelli M, Catena F, Ansaloni L, et al. Complicated intraabdominal infections in Europe: A comprehensive review of the CIAO study. World J Emerg Surg 2012;29(7):36.
19. Oteo J, Pérez-Vázquez M, Campos J. Extended-spectrum b-lactamase producing Escherichia coli: Changing epidemiology and clinical impact. Curr Opin Infect Dis 2010; 23:320-326.
20. Montravers P, Lepape A, Dubreuil L, et al. Clinical and microbiological profiles of community-acquired and nosocomial intra-abdominal infections: Results of the French prospective, observational EBIIA study. J Antimicrob Chemother 2009;63:785-794.
21. Swenson BR, Metzger R, Hedrick TL, et al. Choosing antibiotics for intra-abdominal infections: What do we mean by "high risk" Surg Infect 2009;10:29-39.
22. Kollef MH, Sherman G, Ward S, et al. Inadequate Antimicrobial Workshop Group. Treatment of infections: A risk factor for hospital mortality among critically ill patients. Chest 1999;115:462-474.
23. Roehrborn A, Thomas L, Potreck O, et al. The microbiology of postoperative peritonitis. Clin Infect Dis 2001;33:1513-1519.
24. Mulier S, Penninckx F, Verwaest C, et al. Factors affecting mortality in generalized postoperative peritonitis: Multivariate analysis in 96 patients. World J Surg 2003;27:379-384.
25. Ordoñez CA, Puyana JC. Management of peritonitis in the critically ill patient. Surg Clin North Am 2006;86:1323-1349.
26. Seguin P, Fédun Y, Laviolle B, et al. Risk factors for multidrug-resistant bacteria in patients with post-operative peritonitis requiring intensive care. J Antimicrob Chemother 2010;65:342-346.
27. Augustin P, Kermarrec N, Muller-Serieys C, et al. Risk factors for multi-drug resistant bacteria and optimization of empirical antibiotic therapy in postoperative peritonitis. Crit Care 2010;14:R20.
28. Blot S, De Waele JJ, Vogelaers D. Essentials for selecting antimicrobial therapy for intra-abdominal infections. Drugs 2012;72:17-32.
29. Rice LB. Emerging issues in the management of infections caused by multidrug-resistant gram-negative bacteria. Cleve Clin J Med 2007;74(Suppl 4):S12-S20.
30. Pfaller MA, Segreti J. Overview of the epidemiological profile and laboratory detection of extended-spectrum betalactamases. Clin Infect Dis 2006;42(Suppl 4):S153-S163.
31. Bradford PA. Extended spectrum beta-lactamases in the 21st Century: Characterization, epidemiology and the detection of this important resistance threat. Clin Microbiol Rev 2001;14:933-951.
32. Schultz C, Geerlings S. Plasmid-mediated resistance in Enterobacteriaceae: Changing landscape and implications for therapy. Drugs 2012;72:1-16.
33. Dalhoff A. Global fluoroquinolone resistance epidemiology and implications for clinical use. Interdiscip Perspect Infect Dis 2012;976:273.
34. Hawser SP, Badal RE, Bouchillon SK, et al. Susceptibility of gram-negative aerobic bacilli from intra-abdominal pathogens to antimicrobial agents collected in the United States during 2011. J Infect 2014;68:71-76.
35. Hawser SP, Bouchillon SK, Hoban DJ, et al. Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community-and hospital-associated intra-abdominal infections in Europe: Results of the 2008 Study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother 2010;54:3043-3046.
36. Ben-Ami R, Rodŕguez-Banõ J, Arslan H, et al. A multinational survey of risk factors for infection with extendedspectrum beta-lactamase-producing Enterobacteriaceae in nonhospitalized patients. Clin Infect Dis 2009;49:682-690.
37. Tham J, Odenholt I, Walder M, et al. Extended-spectrum beta-lactamase-producing Escherichia coli in patients with travellers' diarrhoea. Scand J Infect Dis 2010;42:275-280.
38. Jamal WY, Al Hashem G, Khodakhast F, Rotimi VO. Comparative in vitro activity of tigecycline and nine other antibiotics against gram-negative bacterial isolates, including ESBL-producing strains. J Chemother 2009;21: 261-266.
39. Vatopoulos A. High rates of metallo-beta-lactamaseproducing Klebsiella pneumoniae in Greece: A review of the current evidence. Eur Surveill 2008;13.
40. Yigit H, Queenan AM, Anderson GJ, et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 2001;45:1151-1161.
41. Lee J, Patel G, Huprikar S, et al. Decreased susceptibility to polymyxin B during treatment of carbapenem-resistant Klebsiella pneumoniae infection. J Clin Microbiol 2009;47: 1611-1612.
42. Falagas ME, Kasiakou SK. Colistin: The revival of polymyxins for the management of multidrug-resistant gramnegative bacterial infections. Clin Infect Dis 2005;40: 1333-1341.
43. Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by carbapenemase-producing K. pneumoniae: Importance of combination therapy. Clin Infect Dis 2012;55:943-950.
44. Ho J, Tambyah PA, Paterson DL. Multiresistant gramnegative infections: A global perspective. Curr Opin Infect Dis 2010;23:546-553.
45. Karageorgopoulos DE, Kelesidis T, Kelesidis I, Falagas ME. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: A review of the scientific evidence. J Antimicrob Chemother 2008;62:45-55.
46. Giamarellou H, Poulakou G. Multidrug-resistant gramnegative infections: What are the treatment options Drugs 2009;69:1879-1901.
47. Rodŕguez-Martnez JM, Poirel L, Nordmann P. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009;53:4783-4788.
48. Hawser SP, Bouchillon SK, Hoban DJ, Badal RE. In vitro susceptibilities of aerobic and facultative anaerobic gramnegative bacilli from patients with intra-abdominal infections worldwide from 2005-2007: Results from the SMART study. Int J Antimicrob Agents 2009;34:585-588.
49. Hu Y, Li L, Li W, et al. Combination antibiotic therapy versus monotherapy for Pseudomonas aeruginosa bacteraemia: A meta-analysis of retrospective and prospective studies. Int J Antimicrob Agents 2013;42:492-496.
50. Sitges-Serra A, Lopez MJ, Girvent M, et al. Postoperative enterococcal infection after treatment of complicated intraabdominal sepsis. Br J Surg 2002;89:361-367.
51. Burnett RJ, Haverstock DC, Dellinger EP, et al. Definition of the role of Enterococcus in intraabdominal infection: Analysis of a prospective randomized trial. Surgery 1995;118:716-721.
52. Dupont H, Friggeri A, Touzeau J, et al. Enterococci increase the morbidity and mortality associated with severe intra-abdominal infections in elderly patients hospitalized in the intensive care unit. J Antimicrob Chemother 2011;66:2379-2385.
53. Linden PK. Optimizing therapy for vancomycin-resistant enterococci (VRE). Semin Respir Crit Care Med 2007;28: 632-645.
54. Chou YY, Lin TY, Lin JC, et al. Vancomycin-resistant enterococcal bacteremia: Comparison of clinical features and outcome between Enterococcus faecium and Enterococcus faecalis. J Microbiol Immunol Infect 2008;41: 124-129.
55. Jean SS, Fang CT, Wang HK, et al. Invasive infections due to vancomycin-resistant enterococci in adult patients. J Microbiol Immunol Infect 2001;34:281-286.
56. Noskin GA. Vancomycin-resistant enterococci: Clinical, microbiologic, and epidemiologic features. J Lab Clin Med 1997;130:14-20.
57. Chow JK, Golan Y, Ruthazer R, et al. Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit. Clin Infect Dis 2008;46:1206-1213.
58. Pantosti A, Venditti M. What is MRSA Eur Respir J 2009;34:1190-1196.
59. Zetola N, Francis JS, Nuermberger EL, Bishai WR. Community-acquired methicillin-resistant Staphylococcus aureus: An emerging threat. Lancet Infect Dis 2005;5:275-286.
60. Montravers P, Mira JP, Gangneux JP, et al. A multicentre study of antifungal strategies and outcome of Candida spp. peritonitis in intensive-care units. Clin Microbiol Infect 2011;17:1061-1067.
61. Montravers P, Dupont H, Gauzit R, et al. Candida as a risk factor for mortality in peritonitis. Crit Care Med 2006;34: 646-652.
62. Zonios DI, Bennett JE. Update on azole antifungals. Semin Respir Crit Care Med 2008;29:198-210.
63. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: A persistent public health problem. Clin Microbiol Rev 2007;20:133-163.
64. Horn DL, Neofytos D, Anaissie EJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: Data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009;48:1695-1703.
65. Nagy E, Urbán E, Nord CE, ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe: 20 years of experience. Clin Microbiol Infect 2011;17:371-379.
66. Fishman N. Antimicrobial stewardship. Am J Med 2006;119(6 Suppl 1):S53-S61.
67. Davey P, Brown E, Fenelon L, et al. Systematic review of antimicrobial drug prescribing in hospitals. Emerg Infect Dis 2006;12:211-216.
68. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Surg Infect 2010;11:79-109.
69. Sartelli M, Viale P, Catena F, et al. 2013 WSES guidelines for management of intra-abdominal infections. World J Emerg Surg 2013;8:3.
70. Chow AW, Evans GA, Nathens AB, et al. Canadian practice guidelines for surgical intra-abdominal infections. Can J Infect Dis Med Microbiol 2010;21:11-37.
71. McGowan JE Jr. Minimizing antimicrobial resistance: The key role of the infectious diseases physician. Clin Infect Dis. 2004;38:939-942.
72. Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007;44:159-177.
73. Davey P, Brown E, Charani E, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev 2013;30(4):CD003543.